ClinicalTrials.Veeva

Menu

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

H

Handok

Status and phase

Not yet enrolling
Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: HD-P023
Drug: Empagliflozin
Drug: Teneligliptin

Study type

Interventional

Funder types

Industry

Identifiers

NCT06339788
HD-MP-106

Details and patient eligibility

About

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Enrollment

40 estimated patients

Sex

All

Ages

19+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients who are 19 years or older on screening
  • Signed informed consent
  • Healthy Volunteer
  • Other inclusion applies

Exclusion criteria

  • Clinically relevant/significant findings as evaluated by the investigator
  • Other exclusion applied

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

40 participants in 2 patient groups

HD-P023
Experimental group
Description:
One tablet of HD-P023 by oral
Treatment:
Drug: HD-P023
Co-administration of Teneligliptin and Empagliflozin High
Active Comparator group
Description:
One tablet each of Teneligliptin and Empagliflozin High by oral
Treatment:
Drug: Teneligliptin
Drug: Empagliflozin

Trial contacts and locations

0

Loading...

Central trial contact

seungji yoo

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems